Evidence mapPaperPMID 40354545Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

Mitochondria regulate MR1 protein expression and produce self-metabolites that activate MR1-restricted T cells.

Gennaro Prota, Giuliano Berloffa, Wael Awad, Alessandro Vacchini, Andrew Chancellor, Verena Schaefer, Daniel Constantin, Dene R Littler, Rodrigo Colombo, Vladimir Nosi and 3 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gennaro Prota *Experimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.ORCID 0000-0002-7451-2311
Giuliano Berloffa *Experimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.ORCID 0000-0003-3152-9858
Wael Awad *Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-7597-2133
Alessandro VacchiniExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.ORCID 0000-0001-5473-9693
Andrew ChancellorExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.
Verena SchaeferExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.ORCID 0000-0001-7507-5435
Daniel ConstantinExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.
Dene R LittlerInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-5904-1905
Rodrigo ColomboExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.
Vladimir NosiExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.
Lucia MoriExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.
Jamie RossjohnInfection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-2020-7522
Gennaro De LiberoExperimental Immunology, Department of Biomedicine, University Hospital Basel, University of Basel, Basel 4031, Switzerland.ORCID 0000-0003-0853-7868

Funding

Australian Cancer Research Foundation (ACRF) DE220101491HHS | NIH (NIH) RO1 AI148407-01A1Krebsliga Beider Basel (Cancer League of Basel-City and Basel-Country) KLbB-4779-02-2019NIAID NIH HHS R01 AI148407Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030-173240Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030B-192828Swiss Cancer Research Foundation (Swiss Cancer Research) KFS-4707-02-2019
6 · The paper itself

Abstract

Mitochondria coordinate several metabolic pathways, producing metabolites that influence the immune response in various ways. It remains unclear whether mitochondria impact antigen presentation by the MHC-class-I-related antigen-presenting molecule, MR1, which presents small molecules to MR1-restricted T-lymphocytes. Here, we demonstrate that mitochondrial complex III and the enzyme dihydroorotate dehydrogenase are essential for the cell-surface expression of MR1 and for generating uridine- and thymidine-related compounds that bind to MR1 and are produced upon oxidation by reactive oxygen species. One mitochondria-derived immunogenic formylated metabolite we identified is 5-formyl-deoxyuridine (5-FdU). Structural studies indicate that 5-FdU binds in the A'-antigen-binding pocket of MR1, positioning the deoxyribose toward the surface of MR1 for TCR interaction. 5-FdU stimulates specific T cells and detects circulating T cells when loaded onto MR1-tetramers. 5-FdU-reactive cells resemble adaptive T cells and express the phenotypes of naïve, memory, and effector cells, indicating prior in vivo stimulation. These findings suggest that mitochondria may play a role in MR1-mediated immune surveillance.

Indexed as

Histocompatibility Antigens Class IMinor Histocompatibility AntigensMitochondriaT-LymphocytesAnimalsAntigen PresentationDihydroorotate DehydrogenaseHumansLymphocyte ActivationMiceMice, Inbred C57BLOxidoreductases Acting on CH-CH Group DonorsReactive Oxygen SpeciesDihydroorotate DehydrogenaseHistocompatibility Antigens Class IMinor Histocompatibility AntigensMR1 protein, humanOxidoreductases Acting on CH-CH Group DonorsReactive Oxygen Speciesantigen presentationformylated metabolitemitochondriaMR1T cells

Identifiers

PMID40354545
PMCPMC12107159

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.